Press Releases

September 14, 2018
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes

CAMBRIDGE, Mass. , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that the company will be added to the quarterly update of the Russell 2000 ® and 3000

Additional Formats
July 17, 2018
Rubius Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced the pricing of its initial public offering of 10,483,000 shares of common stock at a
Additional Formats
Displaying 1 - 10 of 15